• Colorectal Cancer Info MAIN MENU
  • Screen MAIN MENU
  • Care MAIN MENU
  • Cure MAIN MENU
  • Get Involved MAIN MENU
  • Our Mission MAIN MENU

Subscribe to the Newsletter

What is the NRAS biomarker?


The NRAS gene is present in each of the cells in our body. The gene holds the instructions for making a protein by the same name, NRAS. The normal (wild type) NRAS protein is inside each cell and teams up with a group of proteins (the EGFR/RAS/MAPK pathway) as an “on/off” switch to monitor cells growth, division, and movement. The cancer-causing variations (mutations) in the NRAS gene cause abnormal NRAS proteins that are locked in the “on” position and drive constant and uncontrolled cell division.

What does NRAS mutation mean?


When and how should I have NRAS biomarker testing?


Any patient diagnosed with stage IV, metastatic colorectal cancer, (mCRC) or progresses to stage IV, mCRC should be tested for NRAS mutations according to National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncologists (ASCO) recommendations. It is also recommended to test for KRAS mutations before starting anti-EGFR therapy.

Your doctor may also recommend re-testing the tumor for new or additional mutations when chemotherapy treatment stops working and the stage IV tumor grows again.

What do I do with this information?


Knowing the details of tumor biomarkers can help you and your doctor make decisions about personalized treatment with therapies tailored specifically to the characteristics of your tumor.

  • A mutation in the NRAS gene is a prognostic biomarker for aggressive tumor growth and shorter survival compared to tumors with wild type NRAS.
  • A mutation in the NRAS gene is also a predictive biomarker for a poor response to anti-EGFR treatments like cetuximab or panitumumab and therefore, patients with a NRAS mutation should not receive anti-EGFR drugs alone or in combination with chemotherapy.

What treatment options are available?


Instead, patients with NRAS-mutated colorectal cancer should receive chemotherapy (some examples are FOLFOX, CAPOX, and FOLFIRI) with or without Bevacizumab (an antibody that inhibits the growth of blood vessels and oxygen supply in the tumor).

Currently, there is no specific anti-NRAS therapy but there are ongoing clinical trials with new KRAS/NRAS inhibitors.

What are the potential side effects ?


Every treatment has the potential to cause some side effects. Some people may be more sensitive than others to a particular drug. The response to a specific treatment also depends on your other treatments (for example, radiation) and medications. It may also depend on vitamins and herbal supplements. Tell your doctor and pharmacist about all of your medications, vitamins, and treatments. If you are experiencing severe side effects, call your doctor immediately.

For more on side effects of other chemotherapy regimens, click here.


Download: The NRAS Biomarker

Learn about the NRAS Biomarker.

Download English

Latest Updates

Upcoming Events

Are you sure?

Clicking "Start Over" will empty your resources drawer and take you back to the beginning of the journey customizer. Would you like to continue?

Are you sure?

Clicking "Exit" will permanently close your resource drawer for the rest of the session. If you would like to minimize the drawer and access it from other pages, click the symbol next to "MY RESOURCES". Would you like to permanently exit the drawer?